Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations

ABSTRACT: Targeted next-generation sequencing was performed in patients with IDH2-mutant acute myeloid leukemia to identify genomic mechanisms of primary or acquired resistance to the mutant IDH2 inhibitor enasidenib.

INSTRUMENT(S): -

ORGANISM(S): Homo Sapiens

SUBMITTER: Memorial Sloan Kettering Cancer Center 

PROVIDER: PRJEB26337 | EVA | 2018-04-20

REPOSITORIES: EVA